|
|
|
LifeScienceHistory.com - Check us out on Instagram
Take Your Next Career Step with Lundback
Texas Life Science Industry Directory
Banner Advertising
Please note that we have a new site: LifeScienceHistory.com, "Where history is made daily" under development and
delayed by COVID-19, to be launched in 2023 replacing TexasLifeScience.com. Regrettably, we are working with reduced
staffing and the current industry directory is no longer being maintained, but will be replaced with a new and improved
directory upon the launch of the new site. We apologize for the inconvenience.
Reata Pharmaceuticals, Inc.
| | | Phone: | (972) 865-2219 | Fax: | (800) 998-3206 | Year Established: | 2002 | Ticker: | RETA | Exchange: | NASDAQ | Main Contact: | Dawn C. Bir, CCO | | Other Contacts: | W. Christian Wigley, Ph.D., VP, Research and Founding Scientist Mike Visnick, Ph.D., VP, Discovery Chemistry Robert (Bob) Reed, Ph.D, VP, CMC Joel Proksch, Ph.D., VP, Regulatory & Development Colin Meyer, M.D., CMO & VP, Product Development Arthur Gibson, III, VP, Bioinformatics Warren Huff, Founder, CEO & President Michael D. Wortley, CLO Robin Kral, VP, Licensing and Intellectual Property David Chapman, VP, Marketing
| | Company Description | Reata is a clinical-stage biopharmaceutical company that develops novel therapeutics for patients with serious or life-threatening diseases by targeting molecular pathways involved in the regulation of cellular metabolism and inflammation. Reata’s two most advanced clinical candidates, bardoxolone methyl and omaveloxolone, target the important transcription factor Nrf2 that promotes the resolution of inflammation by restoring mitochondrial function, reducing oxidative stress, and inhibiting pro-inflammatory signaling. | |
|
|
|
|
|